Products
Tools
Education
$1.18
$1.05
$9.56
$0.71
$43.7M
-73.24%
This is a preview of the full version of Prosperse
Verrica Pharmaceuticals reported Q2 2024 financial results, including $4.9M in YCANTH revenue and positive preliminary results from a Phase 2 study of VP-315 for basal cell carcinoma. The company also announced progress in its common warts program and expansion of YCANTH distribution.
N/A
Aug 14, 2024
Date: Nov 19, 2024
Date: Nov 14, 2024